As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
As a core business division of Hetero Healthcare, HHCL Main Division delivers a broad range of quality pharmaceutical products across multiple therapeutic areas. Its expertise includes anti-infectives, gastrointestinal care, pain management, anti-allergics, antivirals, nutraceuticals, and personal care. HHCL Main Division, which is backed by scientific innovation, quality-driven manufacturing, and patient-centric healthcare solutions, provides healthcare professionals with trusted treatment options that promote better patient outcomes and overall wellness.
View by-
